Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/46225
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGonzalez Dorta, Hector-
dc.contributor.authorVERBEECK, Johan-
dc.contributor.authorCREVECOEUR, Jonas-
dc.contributor.authorMorales, Daniel-
dc.contributor.authorLOEDY, Neil-
dc.contributor.authorCohet, Catherine-
dc.contributor.authorWillem , Lander-
dc.contributor.authorMOLENBERGHS, Geert-
dc.contributor.authorHENS, Niel-
dc.contributor.authorKurz, Xavier-
dc.contributor.authorQuinten, Chantal-
dc.contributor.authorABRAMS, Steven-
dc.date.accessioned2025-06-18T13:15:23Z-
dc.date.available2025-06-18T13:15:23Z-
dc.date.issued2025-
dc.date.submitted2025-06-03T14:51:36Z-
dc.identifier.citationThe Lancet. Digital health, 7 (5) (Art N° 100861)-
dc.identifier.urihttp://hdl.handle.net/1942/46225-
dc.description.abstractBackground Several COVID-19 vaccines have been licensed. To support the assessment of safety signals, we developed a toolkit to support COVID-19 vaccine monitoring and benefit-risk assessment. We aim to show the application of our toolkit in the EU using thrombosis with thrombocytopenia syndrome (TTS) associated with the Vaxzevria (AstraZeneca) vaccine as a use case.-
dc.description.sponsorshipThe European Medicines Agency funded the study under the framework service contract EMA/2017/09/PE (lot 1). The authors thank Loris Piccolo, Maria Gordillo Maranon, and Catriona Ester for their critical review of the manuscript. The views expressed in this Article are the personal views of the author(s) and may not be understood or quoted as being made on behalf of or reflecting the position of the EMA or one of its committees or working parties.-
dc.language.isoen-
dc.publisher-
dc.rights2025 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license.-
dc.titleUtilising the Benefit Risk Assessment of Vaccines (BRAVE) toolkit to evaluate the benefits and risks of Vaxzevria in the EU: a population-based study-
dc.typeJournal Contribution-
dc.identifier.issue5-
dc.identifier.volume7-
local.bibliographicCitation.jcatA1-
local.type.refereedRefereed-
local.type.specifiedArticle-
local.bibliographicCitation.artnr100861-
dc.identifier.doi10.1016/j.landig.2025.02.001-
local.provider.typePdf-
local.uhasselt.internationalyes-
item.fullcitationGonzalez Dorta, Hector; VERBEECK, Johan; CREVECOEUR, Jonas; Morales, Daniel; LOEDY, Neil; Cohet, Catherine; Willem , Lander; MOLENBERGHS, Geert; HENS, Niel; Kurz, Xavier; Quinten, Chantal & ABRAMS, Steven (2025) Utilising the Benefit Risk Assessment of Vaccines (BRAVE) toolkit to evaluate the benefits and risks of Vaxzevria in the EU: a population-based study. In: The Lancet. Digital health, 7 (5) (Art N° 100861).-
item.contributorGonzalez Dorta, Hector-
item.contributorVERBEECK, Johan-
item.contributorCREVECOEUR, Jonas-
item.contributorMorales, Daniel-
item.contributorLOEDY, Neil-
item.contributorCohet, Catherine-
item.contributorWillem , Lander-
item.contributorMOLENBERGHS, Geert-
item.contributorHENS, Niel-
item.contributorKurz, Xavier-
item.contributorQuinten, Chantal-
item.contributorABRAMS, Steven-
item.fulltextWith Fulltext-
item.accessRightsOpen Access-
crisitem.journal.eissn2589-7500-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
PIIS2589750025000251.pdfPublished version213.48 kBAdobe PDFView/Open
Show simple item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.